 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...56789101112131415...100101» |
- | letrozole / Generic mfg.
New P3 trial: Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients (clinicaltrials.gov) - May 8, 2024
P3, N=100, Not yet recruiting, Sponsor: Beni-Suef University
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion date, Trial primary completion date: TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) - May 7, 2024
P3, N=144, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- | letrozole / Generic mfg.
Enrollment open: NCI-2021-12428: Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - May 7, 2024
P4, N=60, Recruiting, Sponsor: University of Washington
Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025 Suspended --> Recruiting
- || Soltamox (tamoxifen citrate) / Jazz
Trial completion: The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer (clinicaltrials.gov) - May 6, 2024
P2, N=30, Completed, Sponsor: Johns Hopkins University
Suspended --> Recruiting Active, not recruiting --> Completed
- | letrozole / Generic mfg.
Enrollment open: Letrozole-stimulated Cycle Strategy Versus Artificial Cycle Strategy (LETSACT) (clinicaltrials.gov) - May 6, 2024
P=N/A, N=480, Recruiting, Sponsor: M? ??c Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | hydrocortisone / Generic mfg., flutamide / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - May 3, 2024
P4, N=62, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2024 | Trial primary completion date: Dec 2025 --> May 2024
- || defactinib (VS-6063) / Verastem, avutometinib (VS-6766) / Verastem
New P2 trial: CHAMELEON: A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) - May 1, 2024
P2, N=20, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | hydralazine hydrochloride / Generic mfg., alendronate / Generic mfg.
FDA event, Preclinical, Journal: The significant improvement in ovarian PCOS syndrome using hydralazine and alendronate aromatase inhibitor FDA-approved drugs in Wistar rat models. (Pubmed Central) - Apr 30, 2024
PCOS was induced in rats by intramuscular injection of estradiol valerate (2?mg/kg body weight for 28 days)...So that the natural process of ovulation and the improvement of the histology of polycystic ovaries and its shift towards healthy and active ovaries were observed. This finding supports the potential beneficial effect of hydrolazine and alendronate on improving PCOS complication.
- | letrozole / Generic mfg.
New P2/3 trial: GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients (clinicaltrials.gov) - Apr 30, 2024
P2/3, N=29, Recruiting, Sponsor: Xiaojun Chen
- | letrozole / Generic mfg.
Preclinical, Journal: Letrozole cotreatment progestin-primed ovarian stimulation in women undergoing controlled ovarian stimulation for in vitro fertilization. (Pubmed Central) - Apr 28, 2024
This retrospective study with a limited sample size suggests that the Le PPOS protocol might be an alternative to the PPOS protocol in women undergoing COS and could lead to better pregnancy outcomes. The results should be confirmed using a formal randomized controlled trial.
- | letrozole / Generic mfg.
Preclinical, Journal: The effect of adipose-derived mesenchymal stem cell transplantation on ovarian mitochondrial dysfunction in letrozole-induced polycystic ovary syndrome in rats: the role of PI3K-AKT signaling pathway. (Pubmed Central) - Apr 28, 2024
The results should be confirmed using a formal randomized controlled trial. This study demonstrated that the protective effects of MSC transplantation in regulating mitochondrial dynamics, promoting mitochondrial biogenesis, competing with redox status and inflammation response were mainly mediated through the PI3K-AKT pathway in the PCOS model.
- | letrozole / Generic mfg.
Preclinical, Journal: Effect of a high-fat high-fructose diet on the composition of the intestinal microbiota and its association with metabolic and anthropometric parameters in a letrozole-induced mouse model of polycystic ovary syndrome. (Pubmed Central) - Apr 27, 2024
Both groups fed the HF/HFr diet had significantly lower fecal levels of short-chain fatty acids than the placebo mice fed StD, while the LET + HF/HFr animals had significantly higher concentrations of lipopolysaccharides in blood serum than either the placebo or LET mice fed StD. Opposite correlations were observed between Turicibacter and Lactobacillus and the lipid profile, HF/HFr diet had a much stronger effect on the composition of the intestinal microbiota of prepubertal mice than LET itself.
- | letrozole / Generic mfg.
Retrospective data, Journal: Reassessing the impact of letrozole co-administration in controlled ovarian hyperstimulation: findings from a single-center repeated measures study. (Pubmed Central) - Apr 26, 2024
Opposite correlations were observed between Turicibacter and Lactobacillus and the lipid profile, HF/HFr diet had a much stronger effect on the composition of the intestinal microbiota of prepubertal mice than LET itself. Despite improved oocyte yield, letrozole did not yield any difference in oocyte maturation or embryo outcomes.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal, Adherence: Towards clinical adherence monitoring of oral endocrine breast cancer therapies by LC-HRMS-method development, validation, comparison of four sample matrices, and proof of concept. (Pubmed Central) - Apr 25, 2024
Although parent compounds could be detected in most of the urine samples, metabolites should be included when analyzing urine or OF. Plasma is currently the most suitable matrix due to available reference concentrations.
- KW-2450 / Kyowa Kirin
Phase classification, Combination therapy, Metastases: Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 25, 2024
P1, N=11, Terminated, Sponsor: Kyowa Kirin Co., Ltd.
Plasma is currently the most suitable matrix due to available reference concentrations. Phase classification: P1/2 --> P1
- exemestane / Generic mfg.
Switching from nonsteroidal aromatase inhibitors to exemestane and its impact on menopausal symptoms. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6154;
HR+ breast cancer patients exhibited a significant decrease in all menopausal symptoms when switching from nonsteroidal to steroidal AI. Further research is needed to examine the impact of this switch on a wider range of symptoms.
- Keytruda (pembrolizumab) / Merck (MSD)
Linking the companion diagnostic function of cancer genome profiling to therapy: Investigation of TMB-high predictors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6137;
In multivariate analysis, the history of LET use and the number of PIK3CA mutations were significantly associated with TMB-H. Research shows that PIK3CA mutations are most frequent in patients who have undergone preoperative endocrine therapy with LET (Breast Cancer Res Treat.
- letrozole / Generic mfg.
Neoadjuvant aromatase inhibitor therapy for ER+ breast cancer: The NAOMI trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5185;
P2
It is suggested to increase adherence to adjuvant ET. Additional studies are planned to elucidate mechanisms of resistance in those samples that did not show a decrease in Ki67.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage I-III HER2 negative luminal B breast cancer (DANCER): Preliminary findings from an ongoing phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5103;
P2
Dalpiciclib plus anastrozole or letrozole exhibited biological and clinical activity with manageable toxicities in neoadjuvant treatment for stage I-III luminal B/HER2- BC. Clinical trial information: NCT05640778.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Efficacy, safety, and predictive biomarkers of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer: A phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5100;
The predictive value of genetic alterations and ctDNA status for treatment efficacy warrants further investigation. Clinical trial information: ChiCTR2200062114.
- Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Cost-effectiveness of adjuvant abemaciclib and ribociclib in high-risk, hormone receptor () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5091;
The combination of adjuvant abemaciclib or ribociclib with letrozole is not cost-effective for HR+/HER2- EBC in India in either the best or worst-case scenario. >ICERQALY: Incremental Cost Effectiveness Ratio (ICER) for gain in quality associated life years; ICERLY: ICER for gain in life years; NMB: Net Monetary Benefit.
- Kisqali (ribociclib) / Novartis
Pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib (ribo) in Black patients with metastatic breast cancer (mBC): The LEANORA study. (Hall A; Poster Bd #: 452) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3663;
P4
However, PMs may have more AEs relative to IMs/NMs. Future steps include exploring the impact of rare variants, including ~70 variants in CYP3A 4 and 5, on ribo exposure in this population.
- letrozole / Generic mfg., exemestane / Generic mfg., duloxetine / Generic mfg.
Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI. (Hall A; Poster Bd #: 251) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2869;
P=N/A
Despite AIMT was highly prevalent and associated with non-adherence to AI in this prospective cohort, uptake of recommended SC strategies to manage AIMT seemed suboptimal and inconsistent over time. This large study highlights gaps in the implementation of guideline-concordant SC and warrants efforts to maximize treatment retention among pts with EBC treated with adjuvant AI.
- palazestrant (OP-1250) / Olema Pharma
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors. (Hall A; Poster Bd #: 105b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2564;
P2, P3
This large study highlights gaps in the implementation of guideline-concordant SC and warrants efforts to maximize treatment retention among pts with EBC treated with adjuvant AI. OPERA-01 (NCT06016738) is a multicenter, randomized, open-label, phase 3 clinical trial comparing the efficacy and safety of palazestrant as a single agent to SOC ET (fulvestrant, anastrozole, letrozole, or exemestane) in patients with ER+, HER2
- Ibrance (palbociclib) / Pfizer
Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15). (Hall A; Poster Bd #: 46) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2498;
Palbociclib showed OS over 60 months, comparable to other pivotal clinical trials. Further follow-up analysis of PFS2 and subsequent treatment is warranted.
- lerociclib (G1T38) / Walvax, Pepper Bio
LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer. (Hall A; Poster Bd #: 30) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2482;
P3
Lerociclib with letrozole had an excellent safety profile and significantly prolonged PFS in HR+/HER2- advanced or metastatic BC patients. This benefit was consistent across all clinically relevant subgroups, suggesting lerociclib as a viable first-line therapeutic option with a favorable benefit-risk balance.
- atirmociclib (PF-07220060) / Pfizer
First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2? mBC. (Hall A; Poster Bd #: 253) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2080;
P1/2
PF-07220060 + ET was well tolerated in pts with HR+/HER2? mBC across post-CDK4/6i and CDK4/6i-na
- letrozole / Generic mfg.
GOG 3088: A randomized phase II study of letrozole versus observation in patients with newly diagnosed uterine leiomyosarcoma. (Hall A; Poster Bd #: 503a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1955;
P2
GOG 3088 activated in January of 2024 and expects to enroll across 20 US sites. Clinicaltrials.gov Identifier: NCT05649956.
- AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC). (Hall A; Poster Bd #: 502b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1954;
P1/2
The Atezo+bevacizumab (biomarker unmatched) and Atezo+ipatasertib (PIK3CA/PTEN/AKT1-altered tumors) cohorts have completed accrual...AFT-50B pts will be eligible for inavolisib (PIK3CAm/PTEN and AKT1wt-altered tumors) + letrozole or giredestrant + abemaciclib (RB1wt, estrogen receptor positive tumors)...As a platform study, additional arms may be added, as supported by evolving understanding of EC and molecular targets. EndoMAP is actively enrolling at 20 sites in the US with a target of 25 sites nationwide.
- Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer. (Hall A; Poster Bd #: 501b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1952;
P2
Exploratory endpoints include correlation of baseline molecular biomarkers with clinical outcomes. The trial is open for enrollment.
- Verzenio (abemaciclib) / Eli Lilly
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium. (Hall A; Poster Bd #: 467) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1908;
P1
The trial is open for enrollment. Abemaciclib and letrozole induced a reduction in cellular proliferation in endometrioid endometrial cancer over a relatively short two week time period prior to surgery, suggesting clinical efficacy.
- Verzenio (abemaciclib) / Eli Lilly
Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC). (Hall A; Poster Bd #: 463) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1904;
Baseline and on-treatment ctDNA dynamics may provide an early indication of long-term outcomes and benefit from letrozole/abemaciclib in EC. ctDNA at the time of progression may identify genomic alterations of acquired resistance (such as ESR1, RB1, CCNE1,and ERBB2 alterations) that may guide selection of subsequent therapy.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study. (Hall A; Poster Bd #: 438) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1880;
P2
Research Sponsor: Chia Tai Tianqing Pharmaceutical Group Co. GYNECOLOGIC CANCER.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02. (Hall A; Poster Bd #: 210b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1354;
P2
GYNECOLOGIC CANCER. Participants are randomized 1:1 to receive either 24-week experimental intervention (oral dalpiciclib 150mg once daily for 3 weeks on, 1 week off and oral letrozole 2.5 mg/day) or 24-week standard intervention (intravenous epirubicin 100 mg/m
- amcenestrant (SAR439859) / Sanofi, Verzenio (abemaciclib) / Eli Lilly
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC). (Hall A; Poster Bd #: 193) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1329;
P2
Six months of neoadjuvant endocrine therapy (NET) with the oral SERD amcenestrant is feasible, well-tolerated, and demonstrates anti-proliferative and anti-tumor activity in pre- and postmenopausal pts. NET provides a rich platform for biomarker discovery and investigating response to endocrine therapy.
- Personalized neoadjuvant strategy in ER positive and HER2 negative breast cancer to increase BCS rate (PLATO): A prospective, multicenter, phase II clinical trial. (Hall A; Poster Bd #: 187) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1323;
P2
NET provides a rich platform for biomarker discovery and investigating response to endocrine therapy. Based on the 70-gene assay results from core needle biopsies, high-genomic-risk patients received NCT (anthracycline + cyclophosphamide for 4 cycles, followed by 4 cycles of docetaxel), while low-risk patients underwent 16 weeks of NET with letrozole (
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial. (Hall A; Poster Bd #: 179) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1315;
P2
Despite the exploratory nature of this observation, this is the first significant and profound long-term survival benefit of an anti-cancer vaccine in breast cancer patients reported to date. Additional studies are needed to understand in more detail the underlying mechanisms, and the optimal use of cancer vaccines in breast cancer treatment.
- Verzenio (abemaciclib) / Eli Lilly
Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial. (Hall A; Poster Bd #: 168) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1304;
P2
Highly proliferative tumors Ki67 (?40%) or those with high Recurrence Score (>25) exhibited higher rates of RCB 0-I when treated with chemotherapy, than when treated with letrozole/abemaciclib. This suggests that relying solely on letrozole/abemaciclib as systemic treatment for these tumors may be insufficient.
- Memory mayhem: Hormone therapy causing brain fog in patients with DCIS. (Hall A; Poster Bd #: 167) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1303;
The limitation of the study is the duration of follow up. Usually, patients with DCIS live much longer and can have cognitive effects beyond the window of this study; hence a prospective long-term follow-up study is required to ascertain the relation of HT and cognitive side effects.
- Kisqali (ribociclib) / Novartis
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2? early breast cancer (EBC): NATALEE trial. (E451) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1240;
P3
These findings support the use of RIB in pts with HR+/HER2? EBC at increased risk of recurrence, including pts with N0 disease.
- Ibrance (palbociclib) / Pfizer
A deep learning (Hall A; Poster Bd #: 371) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1105;
A semi-automated workflow enabled rapid and accurate determination of rwPFS in mBC patients receiving a combination chemotherapy regimen. Further evaluation of this workflow to estimate rwPFS in other cancers and therapeutic settings is warranted.
- | letrozole / Generic mfg.
Journal, Metastases: Tumor lysis syndrome following letrozole for locally advanced breast cancer: a case report. (Pubmed Central) - Apr 24, 2024
Further evaluation of this workflow to estimate rwPFS in other cancers and therapeutic settings is warranted. Although TLS typically occurs after chemotherapy initiation, the findings from the present case confirm that this syndrome can also occur after hormonal therapy initiation and should be treated with caution.
- | progesterone / Generic mfg., letrozole / Generic mfg.
Journal: Ideal frozen embryo transfer regime. (Pubmed Central) - Apr 24, 2024
Letrozole is highlighted as a cost-effective and well tolerated option in anovulatory patients. A recent innovative approach combines elements of natural and artificial cycles, showing promise for FET procedures.
- |||||||||| camizestrant (AZD9833) / AstraZeneca, saruparib (AZD5305) / AstraZeneca
New P3 trial: EvoPAR-Breast01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (clinicaltrials.gov) - Apr 24, 2024
P3, N=500, Not yet recruiting, Sponsor: AstraZeneca
- ||||||||| Kisqali (ribociclib) / Novartis
Trial suspension: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Apr 23, 2024
P3, N=3100, Suspended, Sponsor: Novartis Pharmaceuticals
A recent innovative approach combines elements of natural and artificial cycles, showing promise for FET procedures. Recruiting --> Suspended
- || amcenestrant (SAR439859) / Sanofi
Trial completion date, Monotherapy, Metastases: AMEERA-3: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (clinicaltrials.gov) - Apr 23, 2024
P2, N=367, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Suspended Trial completion date: Mar 2024 --> Sep 2024
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Journal, Metastases: Aromatase inhibitors: a useful additional therapeutic option for slowing down advanced bone age in boys with growth hormone deficiency. (Pubmed Central) - Apr 23, 2024
Trial completion date: Mar 2024 --> Sep 2024 When used in addition to rhGH therapy in boys with GHD and advanced BA, AIs were observed to slow down the tempo of BA maturation after 1
- || cabergoline / Generic mfg., letrozole / Generic mfg., temozolomide / Generic mfg.
Clinical, Retrospective data, Review, Journal: Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review. (Pubmed Central) - Apr 23, 2024
AI might be an option for men with resistant prolactinoma who have an increase in PRL levels on TRT. Nevertheless, prospective randomized clinical trials are needed to ensure efficacy and security for this approach.
- | letrozole / Generic mfg.
New P2/3 trial: GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients (clinicaltrials.gov) - Apr 23, 2024
P2/3, N=29, Recruiting, Sponsor: Xiaojun Chen
- | letrozole / Generic mfg., megestrol / Generic mfg.
Trial primary completion date: Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Young Women with Early Endometrial Cancer (clinicaltrials.gov) - Apr 23, 2024
P2, N=104, Recruiting, Sponsor: Fudan University
Nevertheless, prospective randomized clinical trials are needed to ensure efficacy and security for this approach. Trial primary completion date: Mar 2024 --> Mar 2025